Immunomodulation using agonists and antagonists: potential clinical applications

Bibliography

• Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007;13(5):552-9
   PubMed Web of Science ®Google Scholar
• Meyer T, Stockfleth E. Clinical investigations of Toll-like receptor agonists. Expert Opin Investig Drugs 2008;17(7):1051-65
   PubMed Web of Science ®Google Scholar
• Lahiri A, Das P, Chakravortty D. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond. Vaccine 2008;26(52):6777-83
   PubMed Web of Science ®Google Scholar
• Shepard BD, Badley AD. The Biology of TRAIL and the Role of TRAIL-based therapeutics in infectious diseases. Anti Infect Agents Med Chem 2009;8(2):87-101
   Google Scholar
• Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 2007;39(7-8):1462-75
   PubMed Web of Science ®Google Scholar
• Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004;4(4):333-9
   PubMed Web of Science ®Google Scholar
• Kayagaki N, Yamaguchi N, Nakayama M, Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999;189(9):1451-60
   PubMed Web of Science ®Google Scholar
• Kemp TJ, Elzey BD, Griffith TS. Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation. J Immunol 2003;171(1):212-18
   PubMed Web of Science ®Google Scholar
• Takeda K, Smyth MJ, Cretney E, Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth. Cell Immunol 2001;214(2):194-200
   PubMed Web of Science ®Google Scholar
• Liu S, Yu Y, Zhang M, The involvement of TNF-alpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells. J Immunol 2001;166(9):5407-15
   PubMed Web of Science ®Google Scholar
• Sedger LM, Shows DM, Blanton RA, IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J Immunol 1999;163(2):920-6
   PubMed Web of Science ®Google Scholar
• Janssen HL, Higuchi H, Abdulkarim A, Gores GJ. Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression. J Hepatol 2003;39(3):414-20
   PubMed Web of Science ®Google Scholar
• Wagner KW, Punnoose EA, Januario T, Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007;13(9):1070-7
   PubMed Web of Science ®Google Scholar
• Lee TJ, Lee JT, Park JW, Kwon TK. Acquired TRAIL resistance in human breast cancer cells are caused by the sustained cFLIP(L) and XIAP protein levels and ERK activation. Biochem Biophys Res Commun 2006;351(4):1024-30
   PubMed Web of Science ®Google Scholar
• Vaculova A, Hofmanova J, Soucek K, Kozubik A. Different modulation of TRAIL-induced apoptosis by inhibition of pro-survival pathways in TRAIL-sensitive and TRAIL-resistant colon cancer cells. FEBS Lett 2006;580(28-29):6565-9
   PubMed Web of Science ®Google Scholar
• Walczak H, Miller RE, Ariail K, Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5(2):157-63
   PubMed Web of Science ®Google Scholar
• Bodmer JL, Holler N, Reynard S, TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000;2(4):241-3
   PubMed Web of Science ®Google Scholar
• Grosse-Wilde A, Kemp CJ. Metastasis suppressor function of tumor necrosis factor-related apoptosis-inducing ligand-R in mice: implications for TRAIL-based therapy in humans? Cancer Res 2008;68(15):6035-7
   PubMed Web of Science ®Google Scholar
• Hymowitz SG, O'Connell MP, Ultsch MH, A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 2000;39(4):633-40
   PubMed Web of Science ®Google Scholar
• Lawrence D, Shahrokh Z, Marsters S, Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001;7(4):383-5
   PubMed Web of Science ®Google Scholar
• A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas. September 2011. Available from: http://clinicaltrials.gov/ct2/show/results/NCT00400764?term=Apo2L&rank=1
   Google Scholar
• A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab. September 2011. Available from: http://clinicaltrials.gov/ct2/show/NCT00508625?term=TRAIL&rank=4
   Google Scholar
• Takeda K, Yamaguchi N, Akiba H, Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 2004;199(4):437-48
   PubMed Web of Science ®Google Scholar
• Fox NL, Humphreys R, Luster TA, Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy. Expert Opin Biol Ther 2009;10(1):1-18
   Web of Science ®Google Scholar
• HGS-ETR2 to Treat Children With Solid Tumors. October 2011. Available from: http://clinicaltrials.gov/ct2/show/record/NCT00428272?term=TRAIL&rank=14
   Google Scholar
• A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer (NSCLC). April 2011. Available from: http://clinicaltrials.gov/ct2/show/NCT00583830?term=mapatumumab&rank=3
   Google Scholar
• Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma. April 2011. Available from: http://clinicaltrials.gov/ct2/show/NCT00315757?term=mapatumumab&rank=2
   Google Scholar
• Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer. August 2011. Available from: http://clinicaltrials.gov/ct2/show/NCT01307891?term=Tigatuzumab&rank=1
   Google Scholar
• Kang Z, Chen JJ, Yu Y, Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response. Clin Cancer Res 2011;17(10):3181-92
   PubMed Web of Science ®Google Scholar
• Voelkel-Johnson C, King DL, Norris JS. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther 2002;9(2):164-72
   PubMed Web of Science ®Google Scholar
• Lin T, Huang X, Gu J, Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene 2002;21(52):8020-8
   PubMed Web of Science ®Google Scholar
• Griffith TS, Stokes B, Kucaba TA, TRAIL gene therapy: from preclinical development to clinical application. Curr Gene Ther 2009;9(1):9-19
   PubMed Web of Science ®Google Scholar
• Reis CR, van der Sloot AM, Natoni A, Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants. Cell Death Dis 2004;1:e83
   Google Scholar
• Earel JK Jr, VanOosten RL, Griffith TS. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res 2006;66(1):499-507
   PubMed Web of Science ®Google Scholar
• Kandasamy K, Kraft AS. Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region. Mol Cancer Ther 2008;7(5):1091-100
   PubMed Web of Science ®Google Scholar
• Kang S, Park EJ, Joe Y, Systemic delivery of TNF-related apoptosis-inducing ligand (TRAIL) elevates levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and prevents type 1 diabetes in nonobese diabetic mice. Endocrinology 2010;151(12):5638-46
   PubMed Web of Science ®Google Scholar
• Brown AJ, Dusso A, Slatopolsky E. Vitamin D. Am J Physiol 1999;277(2 Pt 2):F157-75
   PubMed Web of Science ®Google Scholar
• Baeke F, Takiishi T, Korf H, Vitamin D: modulator of the immune system. Curr Opin Pharmacol 2010;10(4):482-96
   PubMed Web of Science ®Google Scholar
• Xu H, Soruri A, Gieseler RK, Peters JH. 1,25-Dihydroxyvitamin D3 exerts opposing effects to IL-4 on MHC class-II antigen expression, accessory activity, and phagocytosis of human monocytes. Scand J Immunol 1993;38(6):535-40
   PubMed Web of Science ®Google Scholar
• Penna G, Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000;164(5):2405-11
   PubMed Web of Science ®Google Scholar
• Chen S, Sims GP, Chen XX, Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 2007;179(3):1634-47
   PubMed Web of Science ®Google Scholar
• Boonstra A, Barrat FJ, Crain C, 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001;167(9):4974-80
   PubMed Web of Science ®Google Scholar
• Lemire JM, Archer DC, Beck L, Spiegelberg HL. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr 1995;125(6 Suppl):1704S-8S
   PubMed Web of Science ®Google Scholar
• Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science 1983;221(4616):1181-3
   PubMed Web of Science ®Google Scholar
• Martineau AR, Wilkinson KA, Newton SM, IFN-gamma- and TNF-independent vitamin D-inducible human suppression of mycobacteria: the role of cathelicidin LL-37. J Immunol 2007;178(11):7190-8
   PubMed Web of Science ®Google Scholar
• Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol 1980;9(3):227-31
   PubMed Web of Science ®Google Scholar
• Van Belle TL, Gysemans C, Mathieu C. Vitamin D in autoimmune, infectious and allergic diseases: a vital player? Best Pract Res Clin Endocrinol Metab 2011;25(4):617-32
   PubMed Web of Science ®Google Scholar
• Scott LJ, Dunn CJ, Goa KL. Calcipotriol ointment. A review of its use in the management of psoriasis. Am J Clin Dermatol 2001;2(2):95-120
   PubMedGoogle Scholar
• Barker JN, Ashton RE, Marks R, Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator. Br J Dermatol 1999;141(2):274-8
   PubMed Web of Science ®Google Scholar
• Correale J, Ysrraelit MC, Gaitan MI. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain 2009;132(Pt 5):1146-60
   PubMed Web of Science ®Google Scholar
• Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 1998;128(1):68-72
   PubMed Web of Science ®Google Scholar
• Gregori S, Giarratana N, Smiroldo S, A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002;51(5):1367-74
   PubMed Web of Science ®Google Scholar
• Lim WC, Hanauer SB, Li YC. Mechanisms of disease: vitamin D and inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 2005;2(7):308-15
   PubMedGoogle Scholar
• Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007;7(9):684-700
   PubMed Web of Science ®Google Scholar
• Flaig TW, Barqawi A, Miller G, A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer. Cancer 2006;107(2):266-74
   PubMed Web of Science ®Google Scholar
• Evans TR, Colston KW, Lofts FJ, A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br J Cancer 2002;86(5):680-5
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Hall MC, Stindt D, Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin Cancer Res 2005;11(24 Pt 1):8680-5
   PubMed Web of Science ®Google Scholar
• Attia S, Eickhoff J, Wilding G, Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin Cancer Res 2008;14(8):2437-43
   PubMed Web of Science ®Google Scholar
• Dalhoff K, Dancey J, Astrup L, A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer 2003;89(2):252-7
   PubMed Web of Science ®Google Scholar
• Beer TM, Javle M, Lam GN, Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. Clin Cancer Res 2005;11(21):7794-9
   PubMed Web of Science ®Google Scholar
• Beer TM, Ryan CW, Venner PM, Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007;25(6):669-74
   PubMed Web of Science ®Google Scholar
• Scher HI, Jia X, Chi K, Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 2011;29(16):2191-8
   PubMed Web of Science ®Google Scholar
• Woloszynska-Read A, Johnson CS, Trump DL. Vitamin D and cancer: clinical aspects. Best Pract Res Clin Endocrinol Metab 2011;25(4):605-15
   PubMed Web of Science ®Google Scholar
• Carlberg C, Molnar F. Detailed molecular understanding of agonistic and antagonistic vitamin D receptor ligands. Curr Top Med Chem 2006;6(12):1243-53
   PubMed Web of Science ®Google Scholar
• Brown AJ, Finch J, Grieff M, The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology 1993;133(3):1158-64
   PubMed Web of Science ®Google Scholar
• Brown AJ, Finch JL, Lopez-Hilker S, New active analogues of vitamin D with low calcemic activity. Kidney Int Suppl 1990;29:S22-7
   PubMedGoogle Scholar
• Brown AJ, Slatopolsky E. Vitamin D analogs: therapeutic applications and mechanisms for selectivity. Mol Aspects Med 2008;29(6):433-52
   PubMed Web of Science ®Google Scholar
• Trump DL, Deeb KK, Johnson CS. Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J 2010;16(1):1-9
   PubMed Web of Science ®Google Scholar
• Lagerstrom MC, Schioth HB. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 2008;7(4):339-57
   PubMed Web of Science ®Google Scholar
• Rajagopal S, Rajagopal K, Lefkowitz RJ. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 2010;9(5):373-86
   PubMed Web of Science ®Google Scholar
• Smith NJ, Bennett KA, Milligan G. When simple agonism is not enough: emerging modalities of GPCR ligands. Mol Cell Endocrinol 2011;331(2):241-7
   PubMed Web of Science ®Google Scholar
• Chu ZL, Jones RM, He H, A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 2007;148(6):2601-9
   PubMed Web of Science ®Google Scholar
• Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8(3):235-53
   PubMed Web of Science ®Google Scholar
• Semple G, Fioravanti B, Pereira G, Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119. J Med Chem 2008;51(17):5172-5
   PubMed Web of Science ®Google Scholar
• Harada H, Asano O, Hoshino Y, 2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: their synthesis and structure-activity relationships toward hepatic glucose production induced via agonism of the A(2B) receptor. J Med Chem 2001;44(2):170-9
   PubMed Web of Science ®Google Scholar
• Nemeth ZH, Bleich D, Csoka B, Adenosine receptor activation ameliorates type 1 diabetes. FASEB J 2007;21(10):2379-88
   PubMed Web of Science ®Google Scholar
• Mandala S, Hajdu R, Bergstrom J, Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002;296(5566):346-9
   PubMed Web of Science ®Google Scholar
• Chun J, Brinkmann V. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med 2011;12(64):213-28
   PubMed Web of Science ®Google Scholar
• Blasko E, Haskell CA, Leung S, Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis. J Neuroimmunol 2009;214(1-2):67-77
   PubMed Web of Science ®Google Scholar
• Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 2011;10(1):47-60
   PubMed Web of Science ®Google Scholar
• Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 2000;14(10):1649-60
   PubMed Web of Science ®Google Scholar
• Rosano L, Di Castro V, Spinella F, ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Mol Cancer Ther 2007;6(7):2003-11
   PubMed Web of Science ®Google Scholar
• A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases (ENTHUSE M1). 2010.
   Google Scholar
• ARX-424 in MS (Merck Serono). September 2011. Available from: http://www.merckserono.com/en/science/pipeline/phase_i/phase_1.html
   Google Scholar
• Cohen S, Stemmer SM, Zozulya G, CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. J Cell Physiol 2011;226(9):2438-47
   PubMed Web of Science ®Google Scholar
• Deng H, Liu R, Ellmeier W, Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381(6584):661-6
   PubMed Web of Science ®Google Scholar
• Dragic T, Litwin V, Allaway GP, HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381(6584):667-73
   PubMed Web of Science ®Google Scholar
• Cocchi F, DeVico AL, Garzino-Demo A, Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270(5243):1811-15
   PubMed Web of Science ®Google Scholar
• Lieberman-Blum SS, Fung HB, Bandres JC. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. Clin Ther 2008;30(7):1228-50
   PubMed Web of Science ®Google Scholar
• Gathe J, Diaz R, Fatkenheuer G, Phase 3 trials of vicriviroc in treatment-experienced subjects demonstrate safety but not significantly superior efficacy over potent background regimens. 17th Conference on Retroviruses and Opportunistic Infections 2010
   Google Scholar
• Cohen C, DeJesus E, Mills A, Potent antiretroviral activity of the once-daily CCR5 antagonist INCB009471 over 14 days of monotherapy. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention
   Google Scholar
• Lalezari JP, Saag M, Walworth C, Larson P. An open-label safety study of enfuvirtide injection with a needle-free injection device or needle/syringe: the Biojector 2000 Open-label Safety Study (BOSS). AIDS Res Hum Retroviruses 2008;24(6):805-13
   PubMed Web of Science ®Google Scholar
• Jacobson JM, Lalezari JP, Thompson MA, Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults. Antimicrob Agents Chemother 2010;54(10):4137-42
   PubMed Web of Science ®Google Scholar
• Hutter G, Ganepola S. Eradication of HIV by transplantation of CCR5-deficient hematopoietic stem cells. Sci World J 2011;11:1068-76
   Web of Science ®Google Scholar
• Schmid CL, Bohn LM. Physiological and pharmacological implications of beta-arrestin regulation. Pharmacol Ther 2009;121(3):285-93
   PubMed Web of Science ®Google Scholar
• Whalen EJ, Rajagopal S, Lefkowitz RJ. Therapeutic potential of beta-arrestin- and G protein-biased agonists. Trends Mol Med 2011;17(3):126-39
   PubMed Web of Science ®Google Scholar
• Dimond P, Carlson K, Bouvier M, G protein-coupled receptor modulation with pepducins: moving closer to the clinic. Ann NY Acad Sci 2011;1226(1):34-49
   PubMedGoogle Scholar
• Damaj BB, Becerra CB, Esber HJ, Functional expression of H4 histamine receptor in human natural killer cells, monocytes, and dendritic cells. J Immunol 2007;179(11):7907-15
   PubMed Web of Science ®Google Scholar
• Ash AS, Schild HO. Receptors mediating some actions of histamine. Br J Pharmacol Chemother 1966;27(2):427-39
   PubMed Web of Science ®Google Scholar
• Soll AH, Walsh JH. Regulation of gastric acid secretion. Annu Rev Physiol 1979;41:35-53
   PubMed Web of Science ®Google Scholar
• Esbenshade TA, Fox GB, Cowart MD. Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. Mol Interv 2006;6(2):77-88, 59
   PubMed Web of Science ®Google Scholar
• Thurmond RL, Desai PJ, Dunford PJ, A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. J Pharmacol Exp Ther 2004;309(1):404-13
   PubMed Web of Science ®Google Scholar
• Larsen CM, Faulenbach M, Vaag A, Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356(15):1517-26
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011;117(14):3720-32
   PubMed Web of Science ®Google Scholar
• Abbate A, Kontos MC, Grizzard JD, Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol 2010;105(10):1371-7; e1
   PubMed Web of Science ®Google Scholar
• Joosten LA, Smeets RL, Koenders MI, Interleukin-18 promotes joint inflammation and induces interleukin-1-driven cartilage destruction. Am J Pathol 2004;165(3):959-67
   PubMed Web of Science ®Google Scholar
• Quartier P, Allantaz F, Cimaz R, A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011;70(5):747-54
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev 2010;29(2):317-29
   PubMed Web of Science ®Google Scholar
• Lust JA, Lacy MQ, Zeldenrust SR, Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1beta-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc 2009;2009:84(2):114-22
   Google Scholar
• Harnack U, Johnen H, Pecher G. IL-1 receptor antagonist anakinra enhances tumour growth inhibition in mice receiving peptide vaccination and beta-(1-3),(1-6)-D-glucan. Anticancer Res 2010;30(10):3959-65
   PubMed Web of Science ®Google Scholar
• Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004;4(4):249-58
   PubMed Web of Science ®Google Scholar
• Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002;20:709-60
   PubMed Web of Science ®Google Scholar
• Qi C, Zhu Y, Reddy JK. Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem Biophys 2000;32(Spring):187-204
   PubMedGoogle Scholar
• Vamecq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet 1999;354(9173):141-8
   PubMed Web of Science ®Google Scholar
• Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005;54(8):2460-70
   PubMed Web of Science ®Google Scholar
• Bulhak AA, Jung C, Ostenson CG, PPAR-alpha activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-Kinase/Akt and NO pathway. Am J Physiol Heart Circ Physiol 2009;296(3):H719-27
   PubMed Web of Science ®Google Scholar
• Houseknecht KL, Cole BM, Steele PJ. Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review. Domest Anim Endocrinol 2002;22(1):1-23
   PubMed Web of Science ®Google Scholar
• Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47(4):507-14
   PubMed Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H, Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005;48(9):1726-35
   PubMed Web of Science ®Google Scholar
• Carta AR, Pisanu A, Carboni E. Do PPAR-gamma agonists have a future in Parkinson's disease therapy? Parkinsons Dis 2011;689181
   PubMedGoogle Scholar
• Sakurai T. Targets of the peroxisome proliferator-activated receptor gamma agonist trials for the prevention of Alzheimer disease. Arch Neurol 2011;68(4):542; author reply 42-3
   PubMed Web of Science ®Google Scholar
• Balakumar P, Rose M, Ganti SS, PPAR dual agonists: are they opening Pandora's Box? Pharmacol Res 2007;56(2):91-8
   PubMed Web of Science ®Google Scholar
• Chira EC, McMillen TS, Wang S, Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice. Atherosclerosis 2007;195(1):100-9
   PubMed Web of Science ®Google Scholar
• Kendall DM, Rubin CJ, Mohideen P, Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study. Diabetes Care 2006;29(5):1016-23
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005;294(20):2581-6
   PubMed Web of Science ®Google Scholar
• Hansen BC, Tigno XT, Benardeau A, Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor alpha/gamma agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome. Cardiovasc Diabetol 2011;10:7
   PubMedGoogle Scholar
• Henry RR, Lincoff AM, Mudaliar S, Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 2009;374(9684):126-35
   PubMed Web of Science ®Google Scholar
• Genentech Clinical Development Pipeline: Genentech; 2011
   Google Scholar
• A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus (ROSE). July 5 2011. Available from: http://clinicaltrials.gov/ct2/show/NCT00962832?term=Rontalizumab&rank=1
   Google Scholar
• Atacicept Phase II/III in Generalized Systemic Lupus Erythematosus (April SLE). Aug 1 2011. Available from: http://clinicaltrials.gov/ct2/show/NCT00624338
   Google Scholar
• Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS) (Avonex China). November 2011. Available from: http://clinicaltrials.gov/ct2/show/NCT01181115?term=Avonex&rank=1
   Google Scholar
• Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX). July 2011. Available from: http://clinicaltrials.gov/ct2/show/NCT00928512?term=AIN457&rank=1
   Google Scholar
• A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA). November 2011. Available from: http://clinicaltrials.gov/ct2/show/NCT00642460?term=Actemra&rank=1
   Google Scholar
• Comparative Study of the Clinical Response and Cardiorespiratory Endurance in Early Rheumatoid Arthritis Patients Treated With Tocilizumab or Methotrexate (TOMERA). November 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT01245452?term=Actemra&rank=2
   Google Scholar